Clinical Trial Detail

NCT ID NCT02545504
Title GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Gilead Sciences
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Andecaliximab

Age Groups: adult

Additional content available in CKB BOOST